𝔖 Bobbio Scriptorium

✦ LIBER ✦

Smoking History and Epidermal Growth Factor Receptor Expression as Predictors of Survival Benefit from Erlotinib for Patients with Non–Small-Cell Lung Cancer in the National Cancer Institute of Canada Clinical Trials Group Study BR.21

✍ Scribed by Gary M. Clark; Denni M. Zborowski; Pedro Santabárbara; Keyue Ding; Marlo Whitehead; Lesley Seymour; Frances A. Shepherd

Book ID: 115076627
Publisher: CIG Media Group, LP.
Year: 2006
Tongue: English
Weight: 166 KB
Volume: 7
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2006.n.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I and pharmacokinetic study of d

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB